Separate names with a comma.
I watched @Hazel's video and all I saw was a privileged white person being a gatekeeper of the most important information this forum has to offer....
I’m not sure this will be addressed in their next conference. This study was based on a Safety dose, not a Therapeutic dose. They still had to...
“Although further development of the GSI inhibitor is required, the REGAIN project has helped shape the developmental and regulatory processes...
The lower the Hz number, the farther the drug has to travel. In the example above, 3500Hz is a considerably longer distance FX-322 has to go to...
I agree, if we can ask about this in the upcoming Tinnitus Talk Podcast with Frequency Therapeutics that would be amazing. I might be reaching...
Frequency Therapeutics updated the slides to their corporate presentation. One meaningful change I noticed is on slide 15. The diagram now shows...
I think it would be really great if we had the Tinnitus Talk Podcast reach out to Jeff Karp. He’s extremely receptive and a kind human being and I...
Just wanted to add to this list that someone asked a question with regards to “durability” of the improvements seen in treated patients and both...
Did they convey how much they increased the concentration from the phase 1b trial, or did they convey how much they’re increasing the volume?...
I guess I had higher hopes this could help people with hearing loss lower than 4000 Hz.
Frequency Therapeutics may be backtracking a little bit. On Slide 11: “FX-322 designed to enable hearing in higher frequency ranges critical for...
Frequency posted a detailed corporate presentation this morning: https://investors.frequencytx.com/static-files/6d161090-16f5-49f4-9606-8caceb5a88a1
If you hear back from them, can you ask them about the volume of drug they’ll be injecting and ask them if they’ve increased the concentration of...
It infuriates me that there’s no information with regards to the volume or concentration of FX-322 being injected in the 4 investigational groups.
Kicking off:...
